MedPath

Clinical study of nutritional supplement Supply6 360 to improve gut health.

Phase 2
Registration Number
CTRI/2024/03/063507
Lead Sponsor
Kanari Nutrition Pvt. Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Healthy male and females between 25-35 years of age both inclusive. 2.BMI between 18.5 – 29.9 kg/m2. 3.Subjects should self-report at least two of the following gastrointestinal symptoms: epigastric discomfort, heartburn, bloating, nausea, fullness in the stomach, abdominal pain, or anorexia. 4.Not consuming probiotics, prebiotics, etc. 5.Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.

Exclusion Criteria

1.Participants with major abdominal surgery a history of inflammatory bowel disease or diverticular disease celiac disease allergic diseases including asthma psychiatric disorders and critical systemic illness as assessed by medical history appropriate consultations and laboratory tests

2.Actively having a gut infection

3.History of or complications from malignant tumors

4.Females who are pregnant and have a positive urine pregnancy test planning to be pregnant/lactating or not using reliable methods of contraception

5.Participants with heavy alcohol consumption or smoking or tobacco consumption

6.Any condition that could in the opinion of the investigator preclude the participants ability to complete the study or that may confound study outcomes.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in the Gastrointestinal Symptom Rating Scale (GSRS) scoreTimepoint: From screening visit to end of the study
Secondary Outcome Measures
NameTimeMethod
1.Changes in lipid profile. <br/ ><br>2.Changes in serum vitamin B12 and vitamin D3 levels. <br/ ><br>3.Changes in fatigue severity score. <br/ ><br>4.Changes in the levels of NAD+ (by ELISA) as an indicator of energy. <br/ ><br>5.Percent responders to a reduction in requirement of rescue medication for gastric symptoms (at least 50% reduction in doses or medication events in a month). <br/ ><br>6.Gut microbiota assessment.Timepoint: From screening visit to end of the study
© Copyright 2025. All Rights Reserved by MedPath